Comparison of circuit patency and exchange rates between the original and generic versions of nafamostat mesylate in critically ill adults receiving continuous renal replacement therapy

Background Nafamostat mesylate is widely used as an anticoagulant in continuous renal replacement therapy (CRRT). The generic versions of nafamostat mesylate have identical main components to the original product. However, it is questionable whether the generic versions have the same efficacy as the...

Full description

Bibliographic Details
Published in:	Kosin Medical Journal
Main Authors:	Sujung Heo, Yanghyeon Kim, Nagyeom Lee, Ye Na Kim, Ho Sik Shin, Yeonsoon Jung, Hark Rim
Format:	Article
Language:	English
Published:	Kosin University College of Medicine 2023-03-01
Subjects:	anticoagulant continuous renal replacement therapy nafamostat mesylate
Online Access:	http://www.kosinmedj.org/upload/pdf/kmj-22-137.pdf

Similar Items

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
by: Weiwei Qian, et al.
Published: (2023-09-01)

Nafamostat mesylate versus regional citrate anticoagulation for chronic hemodialysis in patients at high risk of bleeding: a single-center, retrospective study
by: Jiangtao Li, et al.
Published: (2025-12-01)

Anticoagulation application of nafamostat mesylate in patients on continuous renal replacement therapy at a high risk of hemorrhage
by: Jia-rong Ding, et al.
Published: (2024-02-01)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
by: Takahiro Hirayama, et al.
Published: (2017-07-01)

Nafamostat mesylate augments survival in rats afflicted by exertional heat stroke
by: Qingwei Lin, et al.
Published: (2025-05-01)

Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy
by: Ma Xiaobo, et al.
Published: (2025-09-01)

Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study
by: Dan Liu, et al.
Published: (2024-01-01)

Dose of nafamostat mesylate during continuous kidney replacement therapy in critically ill patients: a two-centre observational study
by: Shinya Kameda, et al.
Published: (2024-02-01)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
by: Shinya Kameda, et al.
Published: (2023-01-01)

How do filter types of renal replacement therapy affect survival in critically ill patients? Concerns about adsorption of nafamostat mesylate on AN69 membranes
by: Yiqi Qian, et al.
Published: (2024-09-01)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
by: Yuxin Zhang, et al.
Published: (2020-08-01)

Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury
by: Pei Xie, et al.
Published: (2025-03-01)

Integration of transcriptomics and metabolomics reveals the molecular mechanisms underlying the effect of nafamostat mesylate on rhabdomyolysis-induced acute kidney injury
by: Wenli Guo, et al.
Published: (2022-11-01)

Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats
by: Ji-Hyun Kang, et al.
Published: (2021-09-01)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
by: Hyeon-A Kim, et al.
Published: (2022-06-01)

Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report
by: Yasuhito Suzuki, et al.
Published: (2024-01-01)

Nafamostat mesilate attenuates renal fibrosis by suppressing the IL-17 signaling pathway
by: Weili Liao, et al.
Published: (2025-10-01)

Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples
by: Dong Hwan Lee, et al.
Published: (2025-05-01)

Effect of nafamostat in continuous renal replacement therapy for patients at risk of bleeding
by: TANG Xiaofang*, ZHANG Xu, JIANG Chunming, ZHANG Xijun, TANG Peng, LI Kangfeng
Published: (2025-04-01)

Measuring the Concentration of Serum Syndecan-1 to Assess Vascular Endothelial Glycocalyx Injury During Hemodialysis
by: Keigo Kusuzawa, et al.
Published: (2021-12-01)

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters
by: Megan Neary, et al.
Published: (2023-08-01)

The SARS-CoV-2 Entry Inhibition Mechanisms of Serine Protease Inhibitors, OM-85, Heparin and Soluble HS Might Be Linked to HS Attachment Sites
by: Antony Cheudjeu
Published: (2022-03-01)

Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial
by: Hongyu Yang, et al.
Published: (2025-07-01)

Nafamostat protects against early brain injury after subarachnoid hemorrhage in mice
by: Hirofumi Matsubara, et al.
Published: (2022-01-01)

Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate
Published: (2009-09-01)

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis
by: Hyeon Seok Oh, et al.
Published: (2022-03-01)

Generic Imatinib Mesylate as first-line treatment of chronic myeloid leukemia.
by: Brahim Benzineb, et al.
Published: (2023-04-01)

The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study on patient outcomes and safety
by: Taeil Kim, et al.
Published: (2024-07-01)

Pathophysiological dynamics in the contact, coagulation, and complement systems during sepsis: Potential targets for nafamostat mesilate
by: Qiaolan He, et al.
Published: (2024-10-01)

A Novel Cleavage Pattern of Complement C5 Induced by Chlamydia trachomatis Infection via the Chlamydial Protease CPAF
by: Liang Peng, et al.
Published: (2022-01-01)

Low-dose nafamostat mesilate ameliorates tissue injury and inhibits 5-hydroxytryptamine synthesis in the rat intestine after methotrexate administration
by: Takahiro Yamamoto, et al.
Published: (2023-06-01)

Commentary on “time-dependent selected reaction monitoring-based GC-MS/MS method for estimation of genotoxic impurities in a new antibacterial agent: alalevonadifloxin mesylate”
by: D. J. Snodin, et al.
Published: (2020-11-01)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
by: Yao Lin, et al.
Published: (2022-12-01)

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity
by: İshak Suat Övey, et al.
Published: (2020-03-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

ACE2-Decoy-Conjugated PLGA-PEG Nanoparticles Loaded with Nafamostat for Potent Antiviral Activity
by: Shulin Hou, et al.
Published: (2025-08-01)

Inhibitory potentials of ivermectin, nafamostat, and camostat on spike protein and some nonstructural proteins of SARS-CoV-2: Virtual screening approach
by: Haruna Isiyaku Umar, et al.
Published: (2022-06-01)

Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
by: Malkan Umit Y., et al.
Published: (2018-12-01)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
by: Mahoko Ikeda, et al.
Published: (2023-03-01)